KR102069395B1 - 제i형 및 제ii형 당뇨병의 치료 - Google Patents

제i형 및 제ii형 당뇨병의 치료 Download PDF

Info

Publication number
KR102069395B1
KR102069395B1 KR1020147019062A KR20147019062A KR102069395B1 KR 102069395 B1 KR102069395 B1 KR 102069395B1 KR 1020147019062 A KR1020147019062 A KR 1020147019062A KR 20147019062 A KR20147019062 A KR 20147019062A KR 102069395 B1 KR102069395 B1 KR 102069395B1
Authority
KR
South Korea
Prior art keywords
insulin
delete delete
compound
administration
compounds
Prior art date
Application number
KR1020147019062A
Other languages
English (en)
Korean (ko)
Other versions
KR20140107416A (ko
Inventor
앤드류 지. 레움
마이클 에스. 사포리토
알렉산더 알. 오치만
Original Assignee
멜리어 파마슈티칼스 아이, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 멜리어 파마슈티칼스 아이, 인코포레이티드 filed Critical 멜리어 파마슈티칼스 아이, 인코포레이티드
Publication of KR20140107416A publication Critical patent/KR20140107416A/ko
Application granted granted Critical
Publication of KR102069395B1 publication Critical patent/KR102069395B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147019062A 2011-12-12 2012-12-12 제i형 및 제ii형 당뇨병의 치료 KR102069395B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569496P 2011-12-12 2011-12-12
US61/569,496 2011-12-12
PCT/US2012/069072 WO2013090319A2 (fr) 2011-12-12 2012-12-12 Traitement du diabète de type i et de type ii

Publications (2)

Publication Number Publication Date
KR20140107416A KR20140107416A (ko) 2014-09-04
KR102069395B1 true KR102069395B1 (ko) 2020-01-22

Family

ID=48613352

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147019062A KR102069395B1 (ko) 2011-12-12 2012-12-12 제i형 및 제ii형 당뇨병의 치료

Country Status (15)

Country Link
US (2) US20150190396A1 (fr)
EP (1) EP2790704B1 (fr)
JP (1) JP6152387B2 (fr)
KR (1) KR102069395B1 (fr)
CN (2) CN107007608B (fr)
AU (2) AU2012352480A1 (fr)
BR (1) BR112014014289A8 (fr)
CA (1) CA2859156C (fr)
HK (1) HK1202819A1 (fr)
IL (1) IL233004B (fr)
MX (1) MX359171B (fr)
RU (1) RU2646475C2 (fr)
SG (2) SG11201403207WA (fr)
WO (1) WO2013090319A2 (fr)
ZA (1) ZA201404738B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10863264B2 (en) 2017-01-23 2020-12-08 David Sampson Vibration inducing tactile apparatus
US11254645B2 (en) 2018-01-11 2022-02-22 Bukwang Pharmaceutical Co., Ltd. Method for preparing tolimidone on large scale

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093516A1 (en) 2005-08-22 2007-04-26 Andrew Reaume Methods and formulations for modulating lyn kinase activity and treating related disorders
WO2011150300A1 (fr) * 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prévention de la dégénérescence des cellules pancréatiques bêta

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922345A (en) 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
RU2316339C1 (ru) * 2006-09-13 2008-02-10 Общество С Ограниченной Ответственностью "Концерн О3" Способ получения препарата инсулина для перорального применения
KR20100014480A (ko) * 2007-02-20 2010-02-10 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성제의 확인 방법
NZ579288A (en) * 2007-07-23 2012-06-29 Melior Discovery Inc Methods of activating irs-1 and akt
PT2355829E (pt) * 2008-12-12 2015-02-20 Poxel S A S Combinação de insulina com derivados de triazina e suas utilizações para o tratar diabetes
NZ758966A (en) * 2017-04-10 2024-08-30 Board Of Supervisors Of Louisiana State Univ And Agricultural And Mechanical College Treatment of adipocytes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093516A1 (en) 2005-08-22 2007-04-26 Andrew Reaume Methods and formulations for modulating lyn kinase activity and treating related disorders
US20100278804A1 (en) 2005-08-22 2010-11-04 Melior Pharmaceuticals I, Inc. Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders
WO2011150300A1 (fr) * 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prévention de la dégénérescence des cellules pancréatiques bêta

Also Published As

Publication number Publication date
JP2015513310A (ja) 2015-05-07
SG11201403207WA (en) 2014-09-26
CA2859156C (fr) 2020-10-06
CN104271140A (zh) 2015-01-07
BR112014014289A2 (pt) 2017-06-13
EP2790704A4 (fr) 2015-09-02
HK1202819A1 (en) 2015-10-09
US20200215068A1 (en) 2020-07-09
RU2014128528A (ru) 2016-02-10
US20150190396A1 (en) 2015-07-09
RU2646475C2 (ru) 2018-03-05
KR20140107416A (ko) 2014-09-04
CN107007608A (zh) 2017-08-04
NZ626495A (en) 2016-03-31
CA2859156A1 (fr) 2013-06-20
IL233004A0 (en) 2014-07-31
CN107007608B (zh) 2021-04-23
IL233004B (en) 2020-01-30
EP2790704B1 (fr) 2019-04-03
BR112014014289A8 (pt) 2017-06-13
WO2013090319A2 (fr) 2013-06-20
SG10201604828QA (en) 2016-07-28
JP6152387B2 (ja) 2017-06-21
AU2017204652A1 (en) 2017-07-27
EP2790704A2 (fr) 2014-10-22
AU2012352480A1 (en) 2014-07-17
WO2013090319A3 (fr) 2014-12-04
MX359171B (es) 2018-09-18
CN104271140B (zh) 2016-11-23
MX2014006990A (es) 2015-02-05
AU2017204652B2 (en) 2018-08-16
ZA201404738B (en) 2016-10-26

Similar Documents

Publication Publication Date Title
US20200140425A1 (en) Compounds for the treatment of tuberculosis
US12064432B2 (en) Treatment of adipocytes
US20200215068A1 (en) Treatment of type i and type ii diabetes
US10221169B2 (en) Substituted aminothiazoles for the treatment of tuberculosis
US20220031700A1 (en) Treatment of Acute Respiratory Distress Syndrome (ARDS)
US20210106581A1 (en) Treatment Of Liver Diseases
NZ626495B2 (en) Treatment of type i and type ii diabetes

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant